PURPOSE: To review the literature regarding the role of radiotherapy (RT) in the treatment of patients with radiation-induced malignant gliomas (RIMGs). METHODS AND MATERIALS: A PubMed search of English-language articles dealing with RIMG was performed, yielding 52 articles with 92 patients available for review. RESULTS: Initial tumor types treated with RT included brain tumor in 37 patients (40%), acute lymphoblastic leukemia in 33 (36%), benign disease in 11 (12%), and other in 11 (12%). Median time from RT to development of an RIMG was 8.75 years (range, 2.5-61 years). The RIMG occurred within 10 years after RT in 81% of patients with acute lymphoblastic leukemia/lymphoma, 59% of patients with brain/other, and 18% of patients with benign conditions (p = 0.002). Type of RIMG was glioblastoma in 69 (75%) and anaplastic astrocytoma in 23 (25%). One-, 2-, and 5-year overall survival rates were 29.3%, 7.3%, and 0% for patients with glioblastoma and 59.7%, 30.3%, and 20.2% for patients with anaplastic astrocytoma. For the 85 patients with data regarding treatment for RIMG, 35 underwent reirradiation to a median dose of 50 Gy (range, 30-76 Gy). For patients undergoing reirradiation, 1-, 2- and 5-year overall survival rates were 58.9%, 20.5%, and 6.8%. For those not undergoing reirradiation, they were 15.1%, 3%, and 0% (p = 0.0009). CONCLUSIONS: The RIMG appeared earlier in patients treated for leukemia and lymphoma and latest for those treated for a benign condition. Patients who underwent reirradiation for RIMG have longer survival times compared with those not receiving RT.
PURPOSE: To review the literature regarding the role of radiotherapy (RT) in the treatment of patients with radiation-induced malignant gliomas (RIMGs). METHODS AND MATERIALS: A PubMed search of English-language articles dealing with RIMG was performed, yielding 52 articles with 92 patients available for review. RESULTS: Initial tumor types treated with RT included brain tumor in 37 patients (40%), acute lymphoblastic leukemia in 33 (36%), benign disease in 11 (12%), and other in 11 (12%). Median time from RT to development of an RIMG was 8.75 years (range, 2.5-61 years). The RIMG occurred within 10 years after RT in 81% of patients with acute lymphoblastic leukemia/lymphoma, 59% of patients with brain/other, and 18% of patients with benign conditions (p = 0.002). Type of RIMG was glioblastoma in 69 (75%) and anaplastic astrocytoma in 23 (25%). One-, 2-, and 5-year overall survival rates were 29.3%, 7.3%, and 0% for patients with glioblastoma and 59.7%, 30.3%, and 20.2% for patients with anaplastic astrocytoma. For the 85 patients with data regarding treatment for RIMG, 35 underwent reirradiation to a median dose of 50 Gy (range, 30-76 Gy). For patients undergoing reirradiation, 1-, 2- and 5-year overall survival rates were 58.9%, 20.5%, and 6.8%. For those not undergoing reirradiation, they were 15.1%, 3%, and 0% (p = 0.0009). CONCLUSIONS: The RIMG appeared earlier in patients treated for leukemia and lymphoma and latest for those treated for a benign condition. Patients who underwent reirradiation for RIMG have longer survival times compared with those not receiving RT.
Authors: G Simonetti; Paola Gaviani; E Lamperti; A Innocenti; A Botturi; M Saini; B Pollo; A Silvani Journal: Neurol Sci Date: 2016-06-21 Impact factor: 3.307
Authors: Antonio José Conde-Moreno; Raquel García-Gómez; María Albert-Antequera; Piedad Almendros-Blanco; Ramón De Las Peñas-Bataller; Verónica González-Vidal; José Luis López-Torrecilla; Carlos Ferrer-Albiach Journal: Rep Pract Oncol Radiother Date: 2015-02-20
Authors: Pavlina K Todorova; Eliot Fletcher-Sananikone; Bipasha Mukherjee; Rahul Kollipara; Vamsidhara Vemireddy; Xian-Jin Xie; Peter M Guida; Michael D Story; Kimmo Hatanpaa; Amyn A Habib; Ralf Kittler; Robert Bachoo; Robert Hromas; John R Floyd; Sandeep Burma Journal: Cancer Res Date: 2019-05-14 Impact factor: 12.701
Authors: Waqar Haque; Christopher H Crane; Sunil Krishnan; Marc E Delclos; Milind Javle; Christopher R Garrett; Robert A Wolff; Prajnan Das Journal: Radiat Oncol Date: 2009-11-18 Impact factor: 3.481